Showing 1682 results
-
Press release /Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated…
-
Press release /Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously…
-
Press release /If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional…
-
Press release /Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for…
-
Press release /Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have…
-
Press release /No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1] Innovative study design demonstrates switching between…
-
Ad hoc release /Company finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related…
-
Press release /Novartis ranks third in 2016 ranking Company tops the industry in access-to-medicine management and capacity building Novartis integrated access strategy addressing all income…
-
Press release /The FDA's May 2019 approval of Zolgensma ®, a gene therapy for spinal muscular atrophy (SMA) in pediatric patients less than 2 years of age, marked an important milestone within the SMA community.…
-
Press release /CHMP positive opinion advances efforts to provide first-in-class LABA/LAMA/ICS combination for patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment in the EU. Digital…